Decitabine: a historical review of the development of an epigenetic drug

被引：43
作者：
de Vos, D [1 ]
van Overveld, W [1 ]
机构：
[1] Pharmachem BV, Haarlem, Netherlands
来源：
ANNALS OF HEMATOLOGY | 2005年 / 84卷 / Suppl 1期
关键词：
hypomethylation; MDS; AML; CML; stem cell; sickle cell;
D O I：
10.1007/s00277-005-0008-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis.
引用
收藏
页码：3 / 8
页数：6
相关论文
共 51 条
[11]   Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies [J].
Issa, JPJ ;
Garcia-Manero, G ;
Giles, FJ ;
Mannari, R ;
Thomas, D ;
Faderl, S ;
Bayar, E ;
Lyons, J ;
Rosenfeld, CS ;
Cortes, J ;
Kantarjian, HM .
BLOOD, 2004, 103 (05) :1635-1640
[12]   CELL CYCLE-SPECIFIC REACTIVATION OF AN INACTIVE X-CHROMOSOME LOCUS BY 5-AZADEOXYCYTIDINE [J].
JONES, PA ;
TAYLOR, SM ;
MOHANDAS, T ;
SHAPIRO, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (04) :1215-1219
[13]   CELLULAR-DIFFERENTIATION, CYTIDINE ANALOGS AND DNA METHYLATION [J].
JONES, PA ;
TAYLOR, SM .
CELL, 1980, 20 (01) :85-93
[14]   Results of decitabine (5-Aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia [J].
Kantarjian, HM ;
O'Brien, S ;
Cortes, J ;
Giles, FJ ;
Faderl, S ;
Issa, JP ;
Garcia-Manero, G ;
Rios, MB ;
Shan, JQ ;
Andreeff, M ;
Keating, M ;
Talpaz, M .
CANCER, 2003, 98 (03) :522-528
[15]   Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia [J].
Kantarjian, HM ;
OBrien, SM ;
Keating, M ;
Beran, M ;
Estey, E ;
Giralt, S ;
Kornblau, S ;
Rios, MB ;
deVos, D ;
Talpaz, M .
LEUKEMIA, 1997, 11 (10) :1617-1620
[16]  
KANTARJIAN HM, 1997, LEUKEMIA S1, V11
[17]   2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia [J].
Koshy, M ;
Dorn, L ;
Bressler, L ;
Molokie, R ;
Lavelle, D ;
Talischy, N ;
Hoffman, R ;
van Overveld, W ;
DeSimone, J .
BLOOD, 2000, 96 (07) :2379-2384
[18]   Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2′-deoxycytidine (decitabine) [J].
Lübbert, M ;
Daskalakis, M ;
Kunzmann, R ;
Engelhardt, M ;
Guo, YL ;
Wijermans, P .
LEUKEMIA RESEARCH, 2004, 28 (12) :1267-1271
[19]   Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine [J].
Lübbert, M ;
Wijermans, P ;
Kunzmann, R ;
Verhoef, G ;
Bosly, A ;
Ravoet, C ;
Andre, M ;
Ferrant, A .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :349-357
[20]  
MEULENBELTSNIJD.SJ, 1984, PHARM WEEKBLAD, V119, P1186
123456